TABLE 2.
Cytokine production in PBMC cultures from CE patients and uninfected controls
| Stimulus | Cytokine | Patients (n = 40)
|
Uninfected controls (n = 12)
|
P (patients vs controls) | ||
|---|---|---|---|---|---|---|
| No. testing positive (%) | Mean (range) concn (pg/ml)a | No. testing positive (%) | Mean (range) concn (pg/ml)a | |||
| None | IL-4 | 38 (95) | 0.3 (0–0.9) | 9 (75) | 0.2 (0–1.1) | |
| IL-13 | 4 (10) | 0.01 (0–164) | 5 (42) | 0.1 (0–124) | ||
| IFN-γ | 26 (65) | 0.2 (0–58) | 4 (33) | 0.3 (0–62) | ||
| IL-12 | 19 (48) | 0.01 (0–4.5) | 11 (92) | 0.6 (0.9–3.5) | 10−2 | |
| AgB | IL-4 | 40 (100) | 1.1 (0.3–4.9) | 11 (92) | 0.5 (0–1.12) | 6 × 10−3 |
| IL-13 | 35 (88) | 43.4* (0–2,415) | 5 (42) | 0.1 (0–136) | <10−4 | |
| IFN-γ | 35 (88) | 8.0† (0–523) | 11 (92) | 4.5 (0–94) | ||
| IL-12 | 20 (50) | 0.01 (0–3.8) | 11 (92) | 0.3 (0–3.0) | 4 × 10−3 | |
| SHF | IL-4 | 40 (100) | 1.2 (0.3–5.0) | 10 (83) | 0.4 (0–1.7) | 8 × 10−3 |
| IL-13 | 38 (95) | 182* (0–2,313) | 6 (50) | 0.2 (0–208) | <10−4 | |
| IFN-γ | 40 (100) | 231† (36–1,162) | 12 (100) | 194 (32–1,185) | ||
| IL-12 | 26 (65) | 0.1 (0–2.5) | 12 (100) | 0.5 (0.8–5.5) | ||
a
Statistically significant differences: *, P = 10−2; †, P < 10−4.